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serial subcultures in broth containing sub-MIC concentrations of 
AM 
Results: For all strains the bactericidal activity observed with the 
lower irioculuiii was nullified with the higher one (-3.77kO.59 
versus -0.43?0.19  logic^ CFU/niL change at 24 h with respect to 
TI).  Three strains with AM MIC of 64, 128 and 256mg/L were 
obtained from the parental strain with AM MIC=32. The  activity of 
the AM CIP combination against the strain with higher AM MIC 
was lower than that observed against the parental one (- 1.37 versus 
-3.92 logl,, CFU/niL respectively) 
Conclusion: The clinical use of the AM CIP conibindtioil could 
he considered in selected cases of severe infections by HLGR 
Eiiterococcus f a e c i t i n i  provided that the strain exhibits low-level 
resistance to both agents (AM 464 mg/L and CIP <8 mg/L) and 
its susceptibility to the conibination is demonstrated in vitro using an 
appropriate inoculuni 
Resistance-epidemiology and mechanism 
m] European Antimicrobial Resistance 
Surveillance System: first results 
M.J.W. Sprenger', S.L.A.M. Bronzwaer', H. Aubry-Danioii*, 
W. Goettsch', H .  de Neeling', B. Olsson-Liljequist', M.C.J. Wale'. 
' ~ V ~ < J J I ~  Institutt, of Public Healtb a d  the Enuiroiirttenf, Bilthouen, The 
Netberlawds; 'Risenu h'afionul de S a d  Publique and National REferenie 
Cetrtrefur Awtibiofics, Paris, Frawce; .'Swedi.d~ hst i tutefur  Infe&irs 
Diseasr Corifrol, Stockbulni, Su~cdcn; 'PHLS Atitiniicrobial Susceptibility 
Surucillartce Chit  (AmSSU), CDSC Trent, Queem Medical Cetitre, 
NtJrtirqbam, ( IK 
The  European Antimicrobial Resistance Surveillance System 
(EAKSS), funded by the European Comniission (IIGV) and co- 
ol-dinated by The  Netherlands, IS an international network of 
national surveillance systems aiming to collect comparable and 
reliable antimicrobial resistance data for public health purposes. 
Taking into account laboratory methods as well as epideiinologic 
principles, EAKSS acts as an early warning systeiii, analyzes regional 
differences, assesses risk factors, and provides electronic feedback. For 
the 18-month pilot phase, microbiologists and epideniiologists from 
all E U  Meniber States, pluc Iceland, Norway, and Switzerland, will 
be collecting quantitative resistance data (MICs or Etest results in 
most cases) on Streptocticcirs pncirmoniae (SP) and Staphylococcus atireus 
(SA). For SP, isolates from blood and cerebrospinal fluid will be tested 
against penicillin G, cephalosporins and ciprotloxacin, and for SA 
from blood cultures, against niethicillin and vancomycin. Question- 
naires have been developed to collect information on laboratory 
niethods/procedurcls and catchinent population. More than 400 
laboratories will be participating by sending data via national co- 
ordinators to the centrdl EARSS database. Standardization and 
quality control methodr are being developed in consultation with 
ESCMIL) and the WHO.  Data are expected early in 1999. In 
developing the protocol and questionnaire, the challenge was to 
balance scientific validity and feasibility. A first result i s  that consensus 
has been reached by leading microbiologists and epideiiiiologists on 
the protocol m d  logistic framework. EARSS i s  already acting as a 
catalyst for national surveillance systems. 
1 086 1 Prevalence of resistance t o  MLS antibiotics in 
20 European university hospitals participating 
in the European SENTRY Antimicrobial 
Surveillance Program 
E-J. Schinitz, J. Verhoef, A. Fluit. The SENTRY Pa'articipants (3roirp, 
E(jkman- Winkler Insfitute,for M e d i d  iMicrobiolqy, litrechi, 
The Netherlands 
Objectives: To investigate the prevalence of differcnt forms of 
resistance to macrolide, lincosaniide and streptograniin (MLS) anti- 
biotics in Europe 
Methods: Antimicrobial susceptibility testing of 3653 routine 
clinical pneumococcal, staphylococcal and enterococcal isolates from 
20 European university hospitals from 12 countries. The strains were 
collected during the first year of the SENTRY Antiiii~crobial 
Surveillance Prograni (April 1997 to April 1998) 
Results: Among the 698 Strrptomciis pneumonia? isolates tested, 
72.6% were susceptible to penicillin, 21.2% were intermediate and 
6.2% were highly penicillin resistant. The combined percentages of 
penicillin-intermediate and -resistant strains varied between 0% arid 
55% Geographic differences in erythromycin and clindainycin resist- 
ance strongly reflect variations in susceptibility to penicillin. Seventy- 
eight per cent of all 1554 Staphylomrcirs atireus isolates and 42% of all 
909 CNS isolates were methicillin susceptible. In CNS the associ- 
ation between methicillin resistance and erythroniycin/clindamycin 
resistance w-as not as pronounced as for Staphy/omcrur aimiis. Elcven 
per cent of the 90 Enterococcus.faecium isolates exhibited vancomycin 
resistance, while none of the 403 E. /acralis isolates was vancomycin 
resistant. E..faecirrm isolates were less susceptible to erythroniycin than 
E. j i era l i s  isolates, while the opposite was true for clindamycin 
susceptibility. None of the Streptococcus pneumoiiiae, Sfapbylococcrts 
aweus and E. jieciunr isolates tested had an MIC of 4 mg/L for the 
streptograniin combination quinupristin/dalfopristin 
Conclusions: Geographic differences in erythromycin and 
clindaiiiycin resistance in Streptococcus ptzcwmniae and Stapbylococcus 
a i i r e u  strongly reflect the geographic variations in susceptihility to 
penicillin and methicillin in Europe, respectively 
m] Clonally related cefotaxime-resistant 
Salmonella typhimurium isolates from Greece, 
Russia and Hungary 
P.T. Tassios', M .  Gazouli', E. Tzelepi', E. Milch', N. Kozlova', 
S. Sidorenkoi, L. Tzouvelekis',', N.J. Legakis'. 'Drpartmerit ig. 
Bucteriulocqy, Hellenic Pasterrr Iiistitute, 'Dcprtutenr of Mi( robiolo'qy, 
hfdical School, (hiiuersity of Atbeus, ' h h i t ? a /  Ccriterji ir  Epideniiology, 
Greece 
Objectives: To analyze the niechanisins of resistance to newer 
cephalosporins of Salnioriella tyjdiimirriirin from Greece, Russia and 
Hungary, a i d  deterrnme the genetic relationships of cephalosporin- 
resistant strains 
Methods: Two cefotaxiiiie-resistant S. fypbimriritrin strains from 
Greece, eight froin Russia and three from Hungary were studied. 
They were identified by API20E and 0- and H-antisera. Sus- 
ceptibility to antibiotics was determined by an agar dilution method. 
Resistance determinants were transferred by conjugation and tranr- 
formation. Plasmids were extracted by alkaline lysis. b-Lactaniase 
content was analyzed by isoelectric focusing (IEF). Units of b- 
lactamase activity were determined using nitrocefin. Substrate and 
inhibition profiles of the b-lactaniase preparations were obtained by 
spectrophotonietry. b-Lactaiiiase genes wcre cloned in the p K S K  
phagemid and the nucleotide sequences were determined by the 
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dideoxy termination method. Pulsed-field gel electrophoresis 
(PFGE) of genomic DNA was performed after digestion with X6aI 
Results: PFGE showed that all the examined strains were indis- 
tinguishable or closely related. All were able to transfer resistance to 
cefotaxime through similar plasmids of 10-12 kb. Oximino-b-lactam 
resistance was due to the production of extended-spectrum b- 
lactamases related to the chromosomal class A enzyme of Klebsiella 
oxytoca (plasmidic CTX-M-type b-lactamases). The enzymes preferen- 
tially hydrolyzed cefotaxime, ceftriaxone and aztreonam but not 
ceftazidime. They were inhibited by tazobactam and clavulanate. The 
deduced amino acid sequences of enzymes from three representative 
isolates displayed 98% similarity 
Conclusion: The evidence suggests that a single clone of S. 
typhimurium, resistant to newer cephalosporins due to the production 
of CTX-M b-lactamase, has spread in countries of southern and 
eastern Europe. 
ml Clonal spread of an E. coli strain with an ESBL 
TEM 6-lactamase in Germany 
I. Wiegand, B. Wiedemann, Pharnraceutical Microbiology, Bonn, 
Germany 
Objective: Identification of extended-spectrum B-lactamases 
(ESBLs) of E. coli strains from Germany 
Methods: Seven and 14, respectively, ESBL-positive E. coli isolates 
were detected using Etest strips in two hospitals in the cities of 
Reutlingen and Ulm in October 1995 to February 1996. MICs were 
determined by the broth microdilution method. Epidemiologic 
investigations were performed by biochemical fingerprinting. In 
order to detect TEM P-lactamases, PCRs were carried out with 
6laTEM specific primers. Two PCR products were sequenced for 
the further isolates, restriction fragment length polymorphism 
(RFLP) was used to identify mutations within the amplicon 
Results: The biochemical fingerprinting showed that all strains 
were phenotypically identical except one. AU isolates possessed TEM 
P-lactamase genes. Sequence analysis of the 6laTEM genes of two 
isolates revealed mutations at nucleotide position 512 ( G A ) ,  747 
(T-C) and 914 (G-A), as well as silent mutations in the nucleotide 
positions 434 (C-T) and 602 (GT). The amino acid substitutions 
E104K, M182T and G238S correspond to TEM-52. These muta- 
tions were also found in all other isolates, as revealed by RFLP 
analysis. These data indicate a clonal spread of an E. coli strain with 
TEM-52. The isolate that was phenotypically different probably 
acquired the ESBL by plasmid transfer. It  derived from a patient &om 
whom an E. coli strain of the previously described clone was also 
isolated 
Conclusions: Although the prevalence of E .  coli strains with 
ESBL in Germany is relatively low, there is a need for monitoring, 
as clonal spread may occur 
1 089 I Biochemical and genetic characteristics of a 
new TEM-type extended-spectrum I)-lactamase 
(TEM-29B) with a single amino acid 
replacement 
G. Bou Arevalo, G. Cerver6, J. Martinez-Beltrin. Hospifaf Ramdn y 
Cajd, Micro6iology, Madrid, Spain 
Objectives: To characterize a new extended-spectrum TEM-type 
B-lactamase (ESBL) conferring a moderate degree of resistant to 
ceftazidime (CAZ) by biochemical and genetic methods 
Methods and Results: An E. coli clinical strain isolated from a 
patient previously treated with ceftazidime was studied. MICs (agar 
dilution in mg/L) for the isolate were: cefotaxime 0.1, cefepime, 
cefpirome and aztreonam 0.5-1, and CAZ 16. Clavulanic acid 
restored CAZ activity, thus suggecting an ESBL. Isoelectric focusing 
of the sonicated extract showed one band a t  PI 5.4. By conjugation 
assays, the CAZ resistance was transferred and was associated with a 
plasmid of 57 kbp. Plasmid DNA was digested with EcoRI/HindlII 
and afterwards ligated into the plasmid pBGSl 8.. Transformants 
obtained on LB agar plates supplemented with CAZ and kanamycin 
harbored an identical plasmid with an insert of 2.6 kbp, and showed 
an identical antibiotic profile to the clinical strain. Nucleotide 
sequencing was performed and the comparison with the TEM- 1A 
gene revealed four silent mutations at the nucleotide positions 175, 
226,436 and 604, and another at position 693 producing the change 
Argl64-His. The molecular mass of the 6-lactamase by SDS-PAGE 
was 29 kDa. Kinetic assay revealed that the hydrolysis of CAZ (V,,,,, 
12.1) was higher than those of cefotaxime (V,,,,, 3.7) and aztreonam 
(no hydrolysis detected) 
Conclusions: We report the molecular characterization of an 
ESBL. Previously, TEM-29 (PI 5.42) was characterized by PCR- 
RFLP, which showed the same Arg164-His change (Arlet et al, 
1995). Not knowing whether both enzymes are genetically and 
biochemically identical, we tentatively name this new enzyme TEM- 
29B. 
wl lmipenem resistance in Escherichia coli by loss 
of porins 
J.A.M. van de Klundert', M.H. van Gestel', A.J. de Neeling, 
J.E. Degene?. 'Leiden Uniuersify Medical Center, 'R IVM Bilthouen, 
'liniuersity Hospital Groningew, The Netherlands 
Objectives: Elucidation of resistance mechanisms found in a multi- 
ply antibiotic-resistant clinical isolate of Escherichia coli 
Methods: From a patient with urosepsis, an E.  coli strain was 
isolated that was resistant to all current antibiotics except carba- 
penenis. The patient was treated with imipenem, after which an 
Imipenem-resistant variant emerged. Both strains were typed bio- 
chemically, as well as by molecular methods. Resistance mechanisms 
were analyzed, both phenotypically and genotypically 
Results: The pre- and post-therapy isolates were indistinguishable 
by AP120E strips, pulsed-field gel electrophoresis of chromosomal 
DNA, and RAPD. Resistance to aminoglycosides was attributed to 
AAC(6')IV APH(3'). Two TEM 8-lactamases were detected, both 
with a PI of 5.4. By sequencing of the two genes, only silent 
mutations as compared to TEM-1 were found. EWux activity of the 
clinical isolates did not differ from that of a laboratory E. coli K12 
strain. Imipenem resistance was accompanied by a loss of outer- 
membrane porins. In the laboratory, the pre-therapy strain acquired 
imipenem resistance, also with loss of porins, with a frequency of 
approximately 2 Y 10' 
Conclusions: Iinipenem resistance in Enterobacteriaceae is 
usually due to carbapenemases, or AmpC B-lactamases in combina- 
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tioii with porin deficiency In our strains no such inechanism is  
present. We conclude that resistaiice in the pre-therapy strain is partly 
due to impermeability of the outer membrane, which is still enforccd 
111 the po\t-therapy strain 
1 1  Sequence analysis of the ARI-1 beta-lactamase 
H.M. Ilonald, W. Scaife, S.G.B. Aniyes, H.K. Young. Iliiiiwsity of' 
Dirirdn~, Biolo'qiranl St-iriircs, Drmfec, I K  
Objectives: To dcterrnine the sequence ofthe ARI-1 beta-lactamate 
respoiisible for plasmid-encoded resistance to imipeneiu in the 
clinical isolate of .4rinraibnrtcr haitmurrnii strain 6B92. 
Methods: The  AKI-I beta-lactanlase was extracted and part~ally 
purified by anion exchange and gel exclusion chromatography. 
Purified enzyme was separated by polyacrylaniide gel electrophoresis 
and the first 70 ainino acids at the N-terminus were determined by 
Edman degradation, enabling a degcnerate oligonucleotide probe to 
be designed. This probe was used to detect clones containing the 
6hAKI-1 gene in a DNA librarv prepared froiu the imipenem 
resistance plasmid of .4. he~rmannii strain 6892. DNA sequences were 
determined using an ABI PKISM 377 Automated DNA Sequencer. 
Results: The nucleotide sequence of the hlaARI-1 gene showed 
some honiology to the Bb7OXA-5 gene of Psrudomonns arrtr'qinosa. In 
addition, comparisoii of the deduced amino acid sequence with 
sequences held in the SWISSPROT database revealed moderate 
(35'!6) honiology of the AKI-I eiizynie with CIXA-7, OXA-10 and 
OXA-11 in addition to OXA-5. The beta-lactaniase active site S-T- 
F-K and the conserved triad I<-T-C, characteristic of c1.m D beta- 
lactmiases, we]-e identified. 
Conclusions: The  ARI-1 enzyme, responsible for imipenem 
resist.iiice in '4. Imumanirii 6B92, appears to he related to the OXA 
class I> beta-lactanlaws 
A new strategy to limit R-lactamase induction 
in Enterobacter cloacae 
I>. Pfeifle, I. Wiegand, L1. Wiedeiiianii. C h i i t w j i t y  Roirrr, 
Pliarnraxrf ,  14fikrohiolo~qie, Boiiii, ~ ~ ~ r n z a r r y  
Objectives: Eiiferohartrr iloacac produces a cephalosporinase (AmpC) 
which is iiiducible by p-lactaiii antibiotics. P-Lactamase can also be 
constitutively or semi-constitutively overproduced when the amidase 
ArnpD is modified. P-Lactaiiia\e expression appears to be regulated 
by the level of 'inhydi-oniiiropeptides (aM\), especially by the 
anhydroniuraniylpentapeptide in the cytoplasm. The aMs are releatrd 
by the lytic tranrglyco\ylases from the peptidoglycan. Inhibition of 
these enzymes should stop p-lactmiase induction. One of these lytic 
transglycosylases. Slt 7(1, plays an iniportaiit role in p-lactaniase 
induction and can be inhibited by bulgecin 
Methods: E.  ~-/oarae strains were induced with strongp-lactaiiiase 
inducers and in combinmoii with bulgecin. P-Lactamase activity was 
quantified photometrically. MIC\ for /%lactam antibiotics alone and 
in combination with bulgecin were measured by the broth micro- 
dilution method. High-perforniaiice liquid chroiriatogrdphy analyw 
was used to measure the release of aMs froin the peptidoglycan in 
combiiiation with bulgecin 
Results: Inhibition of the Slt 70 by bulgecin stops P-lactanlase 
induction in E. clmoie wild types m d  in hyperinducible iiiutants. I n  
mutants with constitutive p-lactanuse overproduction, p-lactaniase 
activity decreases. Also, in all tested E .  rloarae strains the MlCs o fp -  
lactaniase-susceptible B-lactani antibiotics decrease 
Conclusion: Inhibition ofthe lytic transglycosyla\ec, especially Slt 
decrease of MlCs 7(1, can stop p-lactamase induction and result in 
of ampC _-lactaiiiase-susceptible fi-lactani antibiotic-s. 
Cloning and nucleotide sequence analysis of a 
gene encoding the AmpC P-lactamase in 
Acinetobacter baumannii 
G. Bou Arevalo, G. Cervero, J. Martinez-Beltrin. Hmpird  Karti6ir y 
Cyjal, hlicr~~bioluyy, R t d r i d ,  S p w r  
Objectives: To clone and sequence the gene encodirig the AmpC 
p-lactamase of "kir2i1fobdfrcr buitnianirii 
Methods and results: An '4. bniri~inrriiii main showing rc\i\tmce 
to all p-lactani antibiotics was studied. By isoelcctrofocusing (IEF) of 
the sonicated extract, three P-lactama\es appexed: pla\iiiid- 
mediated TEM-I p-lactaniase (PI 5.4), J chromo\oinaliy medixed 
p-lactaniasc of pI 7.9, and the presumptive chromosomal ceph.ilo- 
spoririase of pI 9.4. Chromosoiiial I)NA of  the strain was digected 
with HirrdlIl and ligated into the Hitdl11 s ~ t e  of pBGSIX-. Recon- 
biiiant plasmids were introduced into E. iolr TG1 by transformation, 
and colonies were selected on LB agar plates \upplemented with 
ampicillin and kanainycin. Three transforii~aiits were obtained har- 
boring a n  identical recombinant plasmid with an insert of 2.2 kbp. 
IEF of the transformants showed one band dt pl 9.4. The mtihiotic 
protile of the transformants \howed resistance to ~nioxycillin, 
~nioxycilliii-clavulanatc, cephalotin, cefiiroxirne, ccfotaxiiiic, a n d  
ceftazidiiiie. The entire 7.2-kbp fragment was sequenced md only 
one open reading frame was detected. It was 1 152 bp long, m d  coded 
for one 3x3 amino arid protein. The deduced peptide sequciice 
contained motif\ found in serine p-Iactamases. The  protein revealed 
siniilarities (35-42'K) with other AnipC p-lactaiiiasc\. By P<:li and 
using internal aniyC primers, the ~ I W J J C  g m c  wcis iietecteci in 
genetically unrelated '4 baumaiinii strains (REI'-PCI<) 
Conclusions: From a iiiultiresistant z4, huirmunrrii stran the mpC 
gene was cloned, sequenced and analyzed for the first tiiiie. This 
finding will undoubtedly contribute to the delineation of the role of 
Amp<: p-lactamase in P-lacuiii resistance of .4. bairnrnnirii. 
Viral infections (except HIV) 
Combination therapy with interferon and 
ribavirin in patients with chronic hepatitis C 
without virologic response after 2 months of 
interferon therapy: preliminary results 
E Lunel, D. Vitour, C. Payan, The Fontevraud Study Group. 
Luboratuire de Borterio- 1 Trulqje, CHC An'qcr3, .Jn<yrs, Frairrr 
Objectives: It has been deinoiistrated that interferon-alpha (IFN) 
therapy is less efficient in  patients with chronic hepatitis C infected 
by a genotype 1 or 4 or those having a high pretreatment viral load. 
The present study reports preliminary result5 of .idapted ther.ipy 
regarding the genotype and the viral load 
Patients and methods: Inclusion criteria were a7 follows: liver 
biopsy-proven chronic hepdtitis C,  ALT above the upper liniit of 
normal range at least twice in the last h months; m infection by 
genotype 1 or 4 (LiPA 11, Iiinogenetics) or pretreatment viral load 
(bDNA 2.0, Chiron) 3 Y l(1" eq/nil; no HUV or HIV infectionc; no 
decoiiipensated rirrhosis; no previous IFN treatnient; informed 
consent. Patients were followed for biological and biochemical 
parameters every month. All pxiciits receivcd 0 MIU of IFN twice 
